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Abstract
Background: A sizeable body of data demonstrates that membrane ICAM-1 (mICAM-1) plays a significant role in
host defense in a site-specific fashion. On the pulmonary vascular endothelium, mICAM-1 is necessary for normal
leukocyte recruitment during acute inflammation. On alveolar epithelial cells (AECs), we have shown previously that
the presence of normal mICAM-1 is essential for optimal alveolar macrophage (AM) function. We have also shown
that ICAM-1 is present in the alveolar space as a soluble protein that is likely produced through cleavage of
mICAM-1. Soluble intercellular adhesion molecule-1 (sICAM-1) is abundantly present in the alveolar lining fluid of
the normal lung and could be generated by proteolytic cleavage of mICAM-1, which is highly expressed on type I
AECs. Although a growing body of data suggesting that intravascular sICAM-1 has functional effects, little is known
about sICAM-1 in the alveolus. We hypothesized that sICAM-1 in the alveolar space modulates the innate immune
response and alters the response to pulmonary infection.
Methods: Using the surfactant protein C (SPC) promoter, we developed a transgenic mouse (SPC-sICAM-1) that
constitutively overexpresses sICAM-1 in the distal lung, and compared the responses of wild-type and SPC-sICAM-1
mice following intranasal inoculation with K. pneumoniae.
Results: SPC-sICAM-1 mice demonstrated increased mortality and increased systemic dissemination of organisms
compared with wild-type mice. We also found that inflammatory responses were significantly increased in SPC-
sICAM-1 mice compared with wild-type mice but there were no difference in lung CFU between groups.
Conclusions: We conclude that alveolar sICAM-1 modulates pulmonary inflammation. Manipulating ICAM-1
interactions therapeutically may modulate the host response to Gram negative pulmonary infections.
Background
Intercellular adhesion molecule-1 (ICAM-1) is an ~100
kDa molecule belonging to the immunoglobulin super-
gene family. The membrane bound form of this protein
(mICAM-1) serves as a counter-receptor for the b2
integrins, CD11a/CD18 (LFA-1) and CD11b/CD18
(Mac-1), found on leukocytes. Interactions with
mICAM-1 facilitate leukocyte transmigration across the
endothelium [1] and over the surface of alveolar epithe-
lial cells (AECs) in the lung [2]. Studies using gene-
targeted mice lacking ICAM-1 or neutralizing antibodies
have indicated that ICAM-1 is necessary for normal
pulmonary host defense [3-5]. A soluble form of the
molecule, soluble intercellular adhesion molecule-1
(sICAM-1), is found in serum and in the alveolar lining
fluid [6-8]. sICAM-1 in the alveolar space is likely gen-
erated by proteolytic cleavage of mICAM-1 found on
type I alveolar epithelial cells [9].
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fluid of both humans and mice [6,7,10-13]. Like
mICAM-1, sICAM-1 binds to LFA-1/Mac-1 and not
only competes with leukocyte binding to mICAM-1
[14], but also stimulates leukocyte cytokine production
[15]. We have previously demonstrated that isolated
alveolar epithelial cells (AECs), which express features
of the type I cell phenotype, release sICAM-1 in primary
culture [7]. However, little is known regarding the phy-
siologic significance of sICAM-1 in the alveolus. Because
sICAM-1 is abundant in the alveolar lining fluid, and
modulates both leukocyte adhesion and stimulation,
sICAM-1 may modulate AEC-leukocyte interactions in
the alveolus, and thus play an important role in lung
diseases characterized by alveolar inflammation, such as
pneumonia and acute lung injury.
Based on these considerations, we hypothesized that
overexpression of sICAM-1 in the alveolus would modu-
late the innate immune response during acute lung inflam-
mation and infection in mice. To address this hypothesis,
we designed and characterized a genetically modified
mouse that overexpresses sICAM-1 in the alveolus under
control of the surfactant protein C promoter (SPC-
sICAM-1). We evaluated this mouse using an established
model of pulmonary infection with K. pneumoniae,c o m -
paring survival, cellular accumulation and recruitment,
and alveolar macrophage (AM) function in SPC-sICAM-1
and wild-type mice. SPC-sICAM-1 mice demonstrated
increased mortality and increased systemic dissemination
of organisms compared with wild-type mice, but no
change in the burden of organisms within the lung. We
also found that SPC-sICAM-1 mice demonstrated exag-
gerated inflammatory responses compared with wild-type
mice. One potential mechanism underlying these differ-
ences is sICAM-1’s ability to prime alveolar macrophages
for elaboration of cytokines in response to LPS.
Methods
Animals
Pathogen-free wild-type C57BL/6 mice were obtained
from Jackson Laboratories (Bar Harbor, ME) at 6-12
weeks of age. All animals were housed in isolator cages
within the Animal Care Facilities at the Ann Arbor
Department of Veterans Affairs Research Laboratories.
Mice received food and water ad libitum. The experi-
mental protocols were approved by the animal care
committees at the University of Michigan and the Veter-
ans Affairs Medical Center.
Transgenic Mouse Design
T h eb a c k b o n eo ft h et r a n s g e n i cc o n s t r u c tw a sp U C 1 8
containing a 3.7 kB human SPC promoter, a multiple
cloning site, and SV40 small t-intron and polyadenylation
signal, which was kindly provided by Dr. J. Whitsett
(Children’s Hospital, Cincinnati, OH). The truncated
mICAM-1 sequence, with transmembrane and cytoplas-
mic domains removed, was kindly provided by Dr. D.
Wagner (Harvard Medical School, Boston, MA) on a
pBluescript backbone [16]. The truncated ICAM-1
cDNA fragment was cut from the pBluescript plasmid
with EcoR I and ligated into the multiple cloning site of
the pUC18 vector (Figure 1a). The final construct was
verified by sequencing. Its functionality was verified by
transfection into MLE12 cells (ATCC, Manassas, VA), a
cell line derived from human AECs that express SPC,
and measurement of sICAM-1 in the cell culture super-
natants (Figure 1b). The Nde I/Not I linearized transgene
DNA fragment was purified and microinjected into
C57BL/6 fertilized eggs as described [17]. Four founders
were identified and were mated with wild-type C57BL/6
mice. Of the four founders, two were discarded due to
near normal expression of sICAM-1, measured in the
bronchoalveolar lavage (BAL). Both of the two remaining
founders expressed sICAM-1 in the BAL at high levels
but only one transmitted the transgene in the expected
fashion (50% transmission rate to offspring). This foun-
der (SPC-sICAM-1) was mated with C57Bl/6 mice to
produce F1 generation mice for subsequent experiments.
Characterization of SPC-sICAM-1 mice
Mice containing the transgene were identified by poly-
merase chain reaction (PCR). The forward primer was
A
ATG Stop poly A
+24 500 bp
PCR: 687 bp
-3700
3.7 SPC sICAM-1 SV40
B
Figure 1 Design of SPC-sICAM-1 transgene construct and
transfection into MLE12 cell line. The transgene, sICAM-1, was
placed under the control of the human SPC promoter (-3700 to +24
bp). The SV40 cassette provided intronic and polyadenylation
sequences. The approximate locations of primers for genotyping
transgenic mice are indicated (arrowheads) together with the PCR
product (a). Function of the transgene was demonstrated by
transient transfection of the transgene into MLE12 cells (b). sICAM-1
in the cell culture supernatants was measured at 24 and 48 hrs as
shown (n = 3, * P < 0.05).
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SPC gene, 5’-CATATAAGACCCTGGTCACACCTGG-
GAGA-3’, and the reverse primer, 5’-TGTGCGGCAT-
GAGAAATTGGCTCCGTGGTC-3’,w a sd e s i g n e d
specific to the ICAM-1 cDNA region (product size 687
bp). A PCR primer directed to the endogenous mouse
cholecystokinin gene was used as an internal control
(forward: 5’-CTGGTTAGAAGAGAGATGAGCTA-
CAAAGGC-3’, reverse: 5’-TAGGACTGCCATCAC-
CACGCACAGACATAC-3’; product size 361 bp). The
PCR conditions were the same for each primer pair: 92°C
for 2 minutes then 94°C for 30 seconds followed by
annealing at 65°C for 30 seconds followed by elongation
at 72°C for 45 seconds. The latter three steps were
repeated for 34 cycles. The reaction was completed at
72°C for 5 minutes. PCR product sizes were analyzed by
electrophoresis on a 2.2% FlashGel DNA cassette
(Lonza, Rockland, ME) using the FlashGel system
(Lonza). Confirmation of lung specific expression was
performed by isolating total RNA from lung, spleen,
heart, liver, and kidney using the Absolutely RNA Mini-
prep Kit (Strategene, La Jolla, CA) following the manu-
facturer’s instructions. The purified RNA was subjected
to reverse transcriptase PCR with primers specific for
the proSPC-sICAM-1 message (forward primer: 5’-
ACCTGCAGGTCGACTCTAGAGGATCCC-3’; reverse
primer: 5’- TGTGCGGCATGAGAAATTGGCTCCGT-
GGTC-3’; product size 637 bp; Figure 1a). The real
time PCR reaction conditions were as follows: 55°C for
40 minutes, then 95°C for 10 minutes, followed by 95°C
for 30 seconds, 60°C for 1 minutes, and 72°C for 30 sec-
onds. The latter three steps were repeated for 34 cycles.
The resultant product was then analyzed by electro-
phoresis on a 2.2% Lonza gel.
Processing of bronchoalveolar lavage fluid for Western
analysis
BAL was performed in transgenic mice and control mice
using previously described methods [18]. BAL was per-
formed using five 1-ml aliquots of PBS that were pooled.
Typical return was 90-95% of instilled volume. BAL fluid
was centrifuged at 500 × g for 10 minutes at 4°C to
remove whole cells. Diluted proteins from BAL were con-
centrated using a 100 kD molecular weight cut off centri-
fugal filter (Millipore). Supernatants were stored at -70°C
for subsequent analysis of sICAM-1 by Western Blot.
Western analysis of sICAM-1
The samples were denatured in sample buffer [2%
sodium dodecyl sulfate (SDS), 10% glycerol, 62.5 mM
Tris HCl, pH 6.8] at 100°C and separated by SDS-polya-
crylamide gel electrophoresis (PAGE) (10% acrylamide)
under non-reducing conditions, loading 20 μg of protein
in each lane. After PAGE, the separated proteins were
electrophoretically-transferred to PVDF membrane (Bio-
Rad Laboratories, Richmond, CA). Full range protein
molecular weight standards were purchased from Bio-
Rad Laboratories. The PVDF membranes were incu-
bated in 5% bovine serum albumin to block nonspecific
binding and exposed to rat mAb AB796 (R&D Systems,
specific for the extracellular domain of mouse ICAM-1),
or control rat IgG2b antibody (R&D Systems). The
membranes were then incubated with anti-rat secondary
antibody conjugated to horseradish peroxidase (Jackson
ImmunoResearch Laboratories, West Grove, PA). The
membranes were washed extensively in Tris-buffered
saline after each step. Subsequently, the blots were
developed using a chemiluminescence system (ECL
Western Blotting detection system, Amersham, Arling-
ton Heights, IL) according to the manufacturer’s
recommendations.
sICAM-1 ELISA
BAL serum and lung homogenates from mice from
experimental and control groups were analyzed for total
sICAM-1 levels by commercially available ELISA kits
(R&D Systems, Minneapolis, MN). The absorbance was
measured at 450 nm by a microplate autoreader (BioTek,
Winooski, VT), with a correction wavelength set at 570
nm. All measurements were preformed following the
manufacturer’s instructions, and the final concentrations
were calculated by reference to the standard curves.
Preparation of Klebsiella pneumoniae
K. pneumoniae strain 43816, serotype 2 was obtained
from American Type Culture Collection (ATCC, Mana-
ssas, VA). K. pneumoniae was grown overnight with aera-
tion in 25 ml of LB broth (Invitrogen, San Diego, CA), at
37°C on a shaker at 300 rpm. The culture was diluted
1:20 and grown for 45 min at 37°C until it reached 0.1
nm OD. Bacteria were then diluted in sterile phosphate-
buffered saline (PBS) to the appropriate CFU/ml (2500 or
250 CFU/100 μl) for intranasal inoculation. Bacteria were
maintained on ice until inoculation.
Inoculation of mice with K. pneumoniae
Twelve week old transgenic mice and wild-type mice
were anesthetized with inhaled isofluorane and inocu-
lated intranasally with 100 μlo ft h eK. pneumoniae sus-
pension. Appropriate dilutions of the inocula were
plated on LB agar plates to confirm the doses adminis-
tered. Other groups of mice were not exposed to
K. pneumoniae, but were inoculated with 100 μlo fP B S
as negative controls.
Lung harvest for histological examination
At 24 hours post-inoculation, one mouse from each
group was euthanized for lung histology. The lungs
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remove excess blood and inflated with formaldehyde to
improve resolution. The lungs and central airways were
then removed en bloc and fixed in formaldehyde. After
removing the central airways, the lungs were transferred
to histocassettes (Fischer Scientific), incubated in for-
maldehyde, embedded in paraffin and processed for sec-
tioning and staining.
Determination of lung CFU and dissemination of K.
pneumoniae
In order to assess the burden of organisms with the lungs,
mice were inoculated with K. pneumoniae (2500 CFU
in100 μl) and euthanized after 24 hours. The pulmonary
vascular bed was perfused via the right ventricle with
DPBS. Lungs and spleen were removed using sterile tech-
nique, and collected in 1 ml and 0.5 ml of 2× Complete
Buffer (Roche, Nutley, NJ), respectively. The tissues were
then homogenized with an Ultra-Turrax T8 Homogenizer
(IKA-Labortechnik, Germany). Aliquots from lungs and
spleens were serially diluted in DPBS to 10
-9.1 0μlo fe a c h
dilution was plated on LB agar plates (Invitrogen) and
incubated at 37°C. Colony counts for each animal were
determined after 24 hours. A priori, we defined positive
spleen cultures to be > 10 CFU of K. pneumoniae.
Phagocytosis of fluorescent beads by AM
Mice were inoculated intranasally with 100 μlo f5×1 0
7
of FITC-labeled bioparticles (pHrodo Bioparticles Con-
jugates, Invitrogen). Control mice were inoculated with
DPBS. One hour post-inoculation, four mice from each
group were euthanized and BAL was obtained as
described [19]. Fluorescence intensity of each sample
was measured by flow cytometry, using a FACScan cyt-
ometer (Becton Dickinson, Mountain View, CA) with
CellQuest software. A minimum of 10,000 viable cells
was analyzed per sample.
Differential cell counts in total lung lavage by flow
cytometry
Perfused lungs were lavaged with10 ml of Dulbecco’s
PBS with mM EDTA. Cells were washed with PBS and
resuspended at 1 × 10
6 cells per ml of PBS. Before addi-
tion of antibodies, the samples were prepared with a
Live/Dead Fixable Aqua Dead Cell Strain Kit (Invitro-
gen, San Diego, CA). Fc Block was added to all samples
following the manufacturer’s instructions to reduce non-
specific binding of antibodies to the activated cells. For
analysis by flow cytometry, the samples were washed
twice in staining buffer (Difco, Detroit, MI), resuspended
in staining buffer, and incubated for 30 min at 4°C in
the dark with labeled antibodies. The following antibo-
dies were obtained from BD: 1A8 (antimurine Ly-6G;
FITC-conjugated) was used to gate on PMN; M1/70
(antimurine CD11b, PerCP-Cy5.5-conjugated) was used
to gate on monocytes; and 30-F11 (antimurine CD45;
APC-Cy7-conjugated) was used to gate on all leuko-
cytes. The following antibodies were obtained from
eBioscience (San Diego, CA): MTS510 (antimurine
TLR4; PE-conjugated), N418 (antimurine CD11c; Pacific
Blue) was used to gate on mature alveolar macrophages;
and HI30 (antimurine CD45; Pacific Blue) was used to
gate on all leukocytes. Appropriate isotype-matched
controls were used in all experiments. All samples were
analyzed on the BD LSR II flow cytometer with 3 lasers
(488 nm blue, 405 nm violet, and 633 nm HeNe red).
A minimum of 10,000 viable cells was analyzed per sam-
ple, first gating on CD45+ cells and second gating on
live cells using the Live/Dead Fixable Aqua Dead Cell
Strain Kit. Gating on specific leukocytes populations was
performed using antibodies described above. Absolute
numbers of each subset were determined by multiplying
the total cell count by hemacytometer with percentage
results from flow cytometry. Data were collected using
FACS Diva software with automatic compensation and
were analyzed using FlowJo software.
In vitro stimulation of AM with LPS and recombinant
sICAM-1
AM were isolated from wild type C57BL/6 mice by
bronchoalveolar lavage with PBS. The AM were plated
at a concentration of 100,000 cells/well and allowed to
adhere in a 96-well plate for one hour. Cells were incu-
bated individually or in combination with Polymixin B
Sulfate (Sigma Aldrich) (50 μg/ml), recombinant
sICAM-1 (Stem Cell Technologies) (50 μg/ml), and/or
LPS (Escherichia coli-derived; Sigma Aldrich) (1 μg/ml).
Samples were incubated for 24 hours. All incubations
were performed at 37°C and 5% CO2. After the incuba-
tion, the media was recovered and the supernatants
were analyzed by commercially available ELISA kits
(R&D Systems, Minneapolis, MN) for MIP2, KC, and
TNF-a. The addition of Polymixin B had no effect on
cytokine expression induced by sICAM-1 alone, suggest-
ing that recombinant sICAM-1 was not contaminated
with LPS (data not shown).
Statistical Analysis
Data are expressed as means with standard error of the
mean represented by error bars. The data were compared
using a two-tailed Student’s t-test or a Chi square contin-
gency table. If more than two groups were compared an
ANOVA was used. Survival difference between groups
was analyzed using Kaplan-Meier curves and Log-rank
(Mantel-Cox) Test. Differences were considered statisti-
cally significant if p values were < 0.05. All statistical ana-
lysis was performed with the GraphPad Prism 5 package
from GraphPad Software (San Diego, CA).
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SPC-sICAM-1 transgenic mice overexpress sICAM-1 in the
lung
In order to begin to dissect the contribution sICAM-1
to host defense in the distal lung in the setting of acute
infection, we designed a transgenic mouse that would
overexpress sICAM-1 in the alveolar space. We chose
the human SPC promoter to drive expression of
sICAM-1 on a C57BL/6 background using conventional
transgenic technology as described in the Materials and
Methods section. The founder offspring were grossly
indistinguishable from wild-type mice. There was no sig-
nificant difference in weights or in histologic appearance
of the lungs (data not shown). We confirmed lung-
specific mRNA expression of the transgene by perform-
ing real time RT PCR on the lung and multiple other
organs of both SPC-sICAM-1 and wild type mice using
a primer set specific to the transgene sequence (Figure
2a). sICAM-1 protein expression in BAL was about
2-log fold higher in SPC-sICAM-1 (1389 ± 237 ng/ml)
mice than in wild-type mice (13.7 ± 1.6 ng/ml)
(Figure 2b). Increased sICAM-1 protein expression in the
lung did not affect either total protein concentrations in
BAL or sICAM-1 levels in the serum in transgenic mice
compared to wild-type controls (Figure 2c, d).
A western blot of BALF protein from transgenic ver-
sus wild-type mice using an anti-ICAM-1 antibody spe-
cific to the external domain of mICAM-1 demonstrated
a unique100 kDA band (transgene product, black arrow-
head Figure 2e) in the transgenic mice, not present in
the wild type mice. A slightly lower molecular weight
band representing endogenous sICAM-1 was present in
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Figure 2 Characterization of SPC-sICAM-1 transgenic mice. Transgene-specific primers demonstrated lung-specific expression of the SPC-
sICAM-1 transgene in the lungs, with no expression detected in wild-type mice (a). Protein expression in SPC-sICAM-1 in BALF was increased (~2
log fold) over wild type mice (b, *** P < 0.05 by t-test), but did not significantly affect total BALF protein or serum sICAM-1 expression (c, d).
Western analysis of BALF demonstrates a larger protein (~100 kDA, black arrowhead) in SPC-sICAM-1 BALF not present in wild type BALF. The
lighter bands (white arrowhead) represent endogenous processing of sICAM-1. Whole lung mince from a wild type mouse is included for
comparison. Two representative mice are shown for SPC-sICAM-1 (F1 generation) and wild type mice (e).
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(white arrowhead Figure 2e). We have previously shown
that production of sICAM-1 in the alveolar space of
wild-type mice is likely mediated by proteolytic cleavage
of mICAM-1 on the surface of type I AEC [9]. In addi-
tion to proteolytic-mediated production of sICAM-1,
SPC-sICAM-1 mice also generate sICAM-1 through
direct release of the transgene protein from type 2 AEC.
The transgenic sICAM-1 lacks membrane and cytoplas-
mic domains and thus is directly released from the cell.
SPC-sICAM-1 mice have decreased survival compared to
wild-type mice after K. pneumoniae infection
We have previously shown that mutant mice deficient in
mICAM-1 have decreased survival in a model of
K. pneumoniae pneumonia [20]. Subsequent studies sug-
gested that the loss of ICAM-1-mediated interaction
between type I AEC and AM resulted in decreased
macrophage phagocytic and bactericidal activities [20].
It is unclear what role sICAM-1 might have in these
processes. To explore the effects of sICAM-1 in the dis-
tal lung on survival in acute lung infection, we inocu-
lated SPC-sICAM-1 and wild-type mice with 2500 CFU
of K. pneumoniae and assessed survival over 10 days.
sICAM-1 overexpression in the distal lung resulted in
greatly decreased survival following intranasal inocula-
tion with K. pneumoniae (87% or 6.6-fold decrease)
compared to similarly inoculated wild-type mice
(Figure 3). Thus, supraphysiologic levels of sICAM-1 in
the alveolar space significantly increased mortality in the
setting of K. pneumoniae infection.
SPC-sICAM-1 mice infected with K. pneumoniae
demonstrate increased systemic dissemination
compared to wild-type mice
Given the decreased survival of SPC-sICAM-1 mice in a
model of K. pneumoniae infection, we next assessed the
affects of sICAM-1 overexpression on the lung burden and
dissemination of bacteria. To confirm consistent, equiva-
lent inoculation, we assessed lung burden 30 minutes after
inoculation in some mice and observed no differences in
bacterial counts (Figure 4a). After 24 hours, we observed
roughly 3-log fold increase in bacterial counts in the lungs
of both transgenic and wild-type mice compared to the 1/2
hour time point. Despite the increased mortality in SPC-
sICAM-1 mice (Figure 3), there was no difference in the
burden of organisms in the lungs or spleens between the
groups (Figure 4b, d). However, systemic dissemination, as
indicated by positive spleen cultures, was significantly
more frequent in the SPC-sICAM-1 mice versus wild-type
mice (73% and 36%, respectively), suggesting a defect in
the ability of SPC-sICAM-1 mice to contain the infection
in the lung (Figure 4c).
SPC-sICAM-1 mice infected with K. pneumoniae
have increased cellular recruitment compared to
wild-type mice
We next examined whether leukocyte accumulation in the
lung during K. pneumoniae infection was affected by
sICAM-1 overexpression. After 24 hours, the SPC-
sICAM-1 showed a significant increase in BAL leukocytes
compared to wild-type mice (Figure 5a). Lung histology
showed dense and patchy inflammation in SPC-sICAM-1
mice not seen in wild-type mice (Figure 5b, c) confirming
that overexpression of sICAM-1 in the distal lung results
in more exuberant inflammatory cell accumulation. To
further characterize this inflammation, we examined the
recruited cells by flow cytometry using cellular markers
specific for AM, monocytes, and neutrophils. SPC-
sICAM-1 mice showed significantly increased numbers of
neutrophils after 24 hours (Figure 6b, c, d), without signifi-
cant changes in the numbers of mature AM or monocytes.
To determine a potential mechanism explaining the
increased number of acute inflammatory cells in SPC-
sICAM-1mice, we measured chemokines inBALfluidat 24
hrs. MIP2 and KC were increased in SPC-ICAM-1 mice,
although the difference was not statistically significant (54.0 ±
28.8 pg/ml vs 16.5 ± 6.9 pg/ml and 107.8 ± 45.1 pg/ml vs
32.2 ± 7.5 pg/ml, respectively). Thus, high level expression of
sICAM-1 in the distal lungs results in increased cellular
recruitmentinthe lung after infectionwithK. pneumoniae.
SPC-sICAM-1 alveolar macrophage phagocytosis is not
impaired compared to wild-type mice
Having demonstrated a decreased survival and decreased
ability to contain bacterial organisms in SPC-sICAM-1
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Figure 3 Overexpression of sICAM-1 in the distal lung results
in decreased survival after K. pneumoniae infection. SPC-sICAM-
1 mice and wild-type controls were inoculated intranasally with
2500 CFU of K. pneumoniae on day 0 and the percentage of mice
surviving was determined over time. At 10 days, survival was
significantly decreased in the SPC-sICAM-1 mice compared with
infected wild-type controls. * P = 0.0012 compared with wild-type
control mice.
Mendez et al. Respiratory Research 2011, 12:12
http://respiratory-research.com/content/12/1/12
Page 6 of 12mice, we sought to determine whether AM phagocytosis
was compromised in the presence of high levels of
sICAM-1. Because our previous studies [20] show the
importance of mICAM-1 mediated interaction between
AM and AEC in host defense, we assessed AM phagocyto-
sis. SPC-sICAM-1 and wild-ty p em i c ew e r ei n o c u l a t e d
with fluorescently-labeled polystyrene beads by intranasal
instillation. After one hour, AM were collected by lavage
and assessed by flow cytometry. Figures 7a and 7b show
that the percentage of macrophages phagocytosing one or
more beads and the number of beads ingested were similar
between SPC-sICAM-1 and wild-type mice. Thus,
increased levels of sICAM-1 in the alveolar lining fluid do
not modulate macrophage phagocytosis.
AM incubated with sICAM-1 and LPS in vitro results in
synergistic production of TNFa and MIP2
Having detected a trend toward increased intra-alveolar
cytokine and chemokine levels in SPC-sICAM-1 mice
compared to wild-type mice in response to in vivo
K. pneumoniae infection, we next determined whether
sICAM-1 could directly enhance in vitro AM cytokine or
chemokine release. AM isolated from wild-type mice
were incubated with recombinant murine sICAM-1 and/
or LPS. After 24 hours, cell free supernatants were col-
lected and analyzed for TNFa or MIP-2. There was no
detectable TNFa or MIP-2 in supernatants from unsti-
mulated AM (Figure 8a, b). As expected, LPS induced
expression of both TNFa and MIP-2 above baseline.
Recombinant sICAM-1 induced expression of both
TNFa and MIP-2, albeit at much lower levels (32% and
11% of LPS induction, respectively). Interestingly, incuba-
tion with both LPS and sICAM-1 induced a response
from AM that was synergistic. LPS and recombinant
sICAM-1 induction of TNFa and MIP-2 was 2.3× and
1.7× greater, respectively, than expected from an additive
affect. These data demonstrate that sICAM-1 modulates
the AM chemokine and cytokine responses to LPS.
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Figure 4 Increased systemic dissemination, but similar lung burden, occurs 24 hours after K. pneumoniae infection. SPC-sICAM-1 mice
and wild-type mice were inoculated intranasally with 2500 CFU of K. pneumoniae. After 30 minutes (a) and 24 hours (b), the animals were
euthanized, and K. pneumoniae CFU were determined in lung homogenates. The percentage of positive spleen cultures and CFU were
determined at 24 hours(c, d). Data are expressed as CFU per milliliter (mean ± SEM; n = 3 at 30 minutes; n = 14 for wild type and n = 15 for
SPC-sICAM-1 at 24 hours; * P < 0.05 compared with wild-type).
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Page 7 of 12SPC-sICAM-1 mice infected with K. pneumoniae
demonstrate a trend toward increased alveolar leak
To ascertain whether acute lung injury was associated with
increased dissemination and decreased survival in SPC-
SICAM-1 mice infected with K.pneumoniae, we examined
albumin levels in BAL of mice. In these studies, transgenic
and wild-type mice were intranasally inoculated with 250
CFU of K. pneumoniae. At 6 and 24 hours, BAL was col-
lected and albumin was measured from the cell free super-
natant by ELISA. We noted a trend in a sustained increase
in albumin levels at 6 and 24 hours in the SPC-sICAM-1
mice compared to the wild type mice (Figure 9). This sug-
gests that alveolar leak may be a plausible mechanism for
increased dissemination in the SPC-sICAM-1 mice.
Discussion
In these studies, we evaluated the effect of lung targeted
expression of sICAM-1 in the alveolar space in the con-
text of Gram negative pneumonia. There are several key
findings. First, high levels of sICAM-1 in the alveolus
increased mortality after K. pneumonia infection. Sec-
ond, this increased mortality was associated with
increased systemic dissemination of organisms, without
change in the burden of organisms within the lung.
Third, high levels of sICAM-1 in the alveolus did not
affect AM number, phenotype or phagocytic function.
Fourth, high levels of sICAM-1 in the alveolus resulted
in enhanced cellular recruitment of acute inflammatory
cells to the lung after K. pneumonia infection. Finally,
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to K. pneumoniae, for comparison. Total number of cells was determined by counting with a hemacytometer (A). Representative histologic
sections of lungs in wild type (B) and SPC-sICAM-1 mice (C) 24 hours after infection. Data are expressed as mean ± SEM. (n = 6 in all groups;
* P < 0.05 compared with wild-type).
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Page 8 of 12sICAM-1 and LPS interact synergistically to increase
cytokine elaboration by AMs. Taken together, these
findings imply a significant, unique role for sICAM-1 in
modulating the inflammatory response to alveolar
infections.
In this study, we used transgenic technology to direct
expression of the sICAM-1 molecule to the alveolus
using the human SPC promoter. The 3.7 kB human SPC
promoter has been used successfully to drive expression
of GM-CSF in a mouse deficient in GM-CSF to correct
the condition of pulmonary alveolar proteinosis in the
deficient mice [21]. Others have used the human SPC
promoter to direct expression human alpha-1 antitrypsin
to the alveolus to assess development of emphysema in a
smoking mouse model [22]. We used the same promoter
to drive expression of a truncated form of mICAM-1 in
the lung. The founder line that was selected for study
was morphologically and behaviorally indistinguishable
from the wild-type litter mate controls. This founder was
specifically chosen due to its high level of sICAM-1
expression found in the BALF compared to wild-type
mice (100-fold increase). BALF protein examined by
Western Blot demonstrated a discrete band at apparent
molecular weight (~100 kD) that was nearly the same as
that of mICAM-1 (~105 kDA). The size of endogenous
sICAM-1 is ~90 kDA [7,23]. We have previously shown
that endogenous sICAM-1 in the alveolus is most likely
proteolytically cleaved from mICAM-1 on the surface of
type I AEC [9]. ICAM-1 is heavily glycosylated and its
apparent molecular weight can vary [24]. Because sequen-
cing confirmed that the transgene actually lacked the
intracellular and transmembrane portions of ICAM-1
(data not shown), it is most likely that the increased
apparent molecular weight of transgenic sICAM-1 is a
result of post-translational processing, such as differential
glycosylation.
These experiments demonstrate that alveolar sICAM-1
overexpression alters the response to infection. Until
now, much of the focus on ICAM-1 in lung inflamma-
tion has been related to the membrane-bound form and
its role in leukocyte trafficking [4,5,25,26]. mICAM-1
and sICAM-1 are expressed and regulated uniquely by
AM
0
2
4
6
0 24
8
10
C
e
l
l
 
N
u
m
b
e
r
 
(
x
1
0
5
)
a
Monocytes
0
200
400
600
800
1000
0 24
C
e
l
l
 
N
u
m
b
e
r
b PMN
0
0 24
*
]
1
2
3
4
5
C
e
l
l
 
N
u
m
b
e
r
 
(
x
1
0
5
)
cd
C
D
4
5
FSC FSC
L
y
6
G
C
D
1
1
c
CD11b
CD45+ Live
Ly6G- subset
6
G
Figure 6 Increased pulmonary inflammation in SPC-sICAM-1 mice after K. pneumoniae infection is due to recruitment of both
mononuclear cells and neutrophils. SPC-sICAM-1 mice and wild-type mice were intranasally inoculated with 250 CFU of K. pneumoniae. After 24
hours, the animals were euthanized, and whole lung lavage was performed. Cells were examined by flow cytometry with a gating strategy to
identify leukocyte subpopulations as described in materials and methods (a, representative plot, SPC-ICAM-1 at 24 hours). SPC-sICAM-1 had greater
accumulation of neutrophils (b), AM (c), and monocytes (d), compared to wild-type at 24 hours, although the differences in AM and monocyte
numbers did not reach statistical significance. Data are expressed as mean ± SEM. (n = 6 in all groups; * P < 0.05 compared to wild-type).
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Page 9 of 12type I AEC [9]. Therefore, we hypothesized that altera-
tion in the amount of sICAM-1 in the alveolus would
alter the inflammatory response. Our results demonstrate
that excess sICAM-1 in the alveolus in the setting of K.
pneumoniae infection results in decreased survival. It is
possible this effect on mortality might be a result of inhi-
bition of AM-AEC interactions mediated by mICAM-1
due to blockade of AM cell surface ligands by the high
levels of sICAM-1. Thus sICAM-1 might be playing a
role similar to that of other soluble receptors such as syn-
decans or receptor for advanced glycation end products
(RAGE) [27,28]. However, overexpression of sICAM-1
results in a response that differs in significant ways from
that found either in ICAM-1 deficient mice or with anti-
body-mediated neutraliza t i o no fI C A M - 1i nt h el u n g
[4,5]. In contrast to the circumstance in ICAM-1 defi-
cient mice, neither the burden of organisms in the lung
nor the ability of AM to phagocytose FITC-labeled beads
in vivo was altered by overexpression of sICAM-1. How-
ever, despite similar numbers of organisms in the lung,
inflammatory cell recruitment was in fact increased in
SPC-sICAM-1 mice compared to wild-type mice. One
may speculate that subtle impairment of AM activity
results in excessive inflammation, which in turn contri-
butes to lung injury, impaired barrier function, and
increased systemic dissemination of infection. Our find-
ings highlight the delicate balance required in the lung to
both protect from infectious insults and preserve func-
tional barrier to the outside world.
The mechanism(s) of decreased survival in the SPC-
sICAM-1 mice in the setting of K. pneumoniae are likely
complex and related to more than one factor. In our
previous work, mICAM-1 deficient mice infected with
K. pneumoniae also had decreased survival [20]. We
demonstrated that bacterial phagocytosis and killing by
AM and neutrophils was enhanced by the interaction
with mICAM-1 on AEC. We attributed the decreased
survival in the ICAM-1 deficient mice to the loss of
mICAM-1-mediated interactions between AEC and AM
that promote AM lateral migration, phagocytosis and
bacterial killing. It is possible that, in mice overexpres-
sing sICAM-1 in the lung, competitive binding of
sICAM-1 to the normal counter receptors of mICAM-1
on AM, CD11a/CD18 (LFA-1) and CD11b/CD18
(Mac-1), prevents this important interaction. Interest-
ingly, in the present study we found that supraphysiologic
sICAM-1 does not impair AM phagocytosis of fluores-
cent beads in vivo, suggesting that lateral mobility and
phagocytic activity of AM remain largely intact in these
mice. This preservation of AM phagocytosis may reflect
incomplete blockade of mICAM-1-mediated effects by
sICAM-1. Despite relatively normal phagocytosis by AM,
the efficiency of bacterial killing in vivo is affected. At 24
hours, there is no significant difference in burden of
K. pneumoniae between SPC-sICAM-1 and wild type
mice, but there is increased accumulation of acute
inflammatory cells, including neutrophils, in the lungs of
SPC-sICAM-1 mice compared to wild-type mice at 24
hours. Thus the efficiency of bacterial clearance is
decreased in the SPC-sICAM-1 mice. We postulate that
this enhanced inflammation, coupled with increased
TNF-a production by alveolar macrophages, ultimately
leads to increased systemic dissemination of infection.
One limitation of our transgenic design is that sICAM-
1i sc o n s t i t u t i v e l yp r o d u c e db yt y p eI IA E C .T h u s ,t h e
endogenous mechanisms regulating shedding of sICAM-
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Figure 7 In vivo phagocytosis of labeled microbeads by AM is
similar in SPC-sICAM-1 and wild-type mice. Mice were lightly
anesthetized and intranasally inoculated with 5 × 10
7 FITC-
conjugated polystyrene microbeads (1.7 micron). After 1 hour, mice
were euthanized, and AM were recovered by whole lung lavage.
Cells were recovered by centrifugation and examined by flow
cytometry. Data are expressed as mean ± SEM for the percentage
of AM that have engulfed beads (A) and the percentage of cells
ingesting 1, 2, or > 2 beads (B). (n = 5 for all groups; no significant
differences between groups).
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Page 10 of 121 form type I AEC become minimized. In this setting,
overexpression of sICAM-1 may overwhelm the host’s
ability to modulate local levels of sICAM-1. This may
lead to unchecked activation and subsequently exagger-
ated inflammation that may be the cause of the decreased
survival we observed in the K. pneumonia infection.
Previous studies examining the role of ICAM-1 in lung
inflammation have focused on the role of ICAM-1 in
recruitment of leukocytes and the use of ICAM-1 blocking
antibodies or ICAM-1 deficient mice. What has not been
addressed is whether there are differential effects of
mICAM-1 and sICAM-1 on the inflammatory cascade. In
experiments designed to block ICAM-1, it is likely that
both mICAM-1 and sICAM-1 being blocked [4,5,25,26]. If
sICAM-1 is functionally active, it is important to under-
stand how to contrast its effects on leukocytes with the
effects of mICAM-1. In studies using ICAM-1 deficient or
mutant mice, the goal has generally been to study a mouse
deficient in mICAM-1. However, in some instances, trans-
genic mice deficient in normal mICAM-1 are still capable
of expressing sICAM-1, possibly through alternative spli-
cing and subsequent cleavage [29]. In order to separate
the roles of mICAM-1 and or sICAM-1 in the alveolar or
vascular compartments, it may be necessary to reintroduce
either sICAM-1 or a ‘noncleavable’ membranous ICAM-1
into ICAM-1 knockout mice.
Conclusions
In summary, our study shows that overexpression of
sICAM-1 in the alveolus has a major impact upon host
defense in the setting of K. pneumoniae infection. In
combination with previous data, our data demonstrate
that sICAM-1 has functional effects that influence cellu-
lar recruitment and AM activation in the setting of
acute infection. This suggests that an appropriate bal-
ance of ICAM-1 with an optimal amount of local
sICAM-1 in the alveolus may be critical for optimal AM
function, activation, and leukocyte recruitment.
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Figure 9 K. pneumoniae infection of SPC-sICAM-1 mice may be
associated with greater alveolar leak compared to wild type
mice. SPC-sICAM-1 mice and wild-type mice were intranasally
inoculated with 250 CFU of K. pneumoniae. After 6 and 24 hours, the
animals were euthanized, and whole lung lavage was performed.
Albumin was measured by ELISA of cell free supernatant. Data are
expressed as mean ± SEM. (n = 6 for all groups).
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